Gorlin Syndrome Market

Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-–Goltz syndrome, is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows the high level of penetrance and variable expressiveness.

It has also been observed that the estimated prevalence of NBCCS has no observed sex predilection i.e., the male-to-female ratio is 1:1.

As per the study conducted by M. Lorenzo et al., “the estimated prevalence of Gorlin Syndrome varies from 1/57,000 to 1/256,000”.

The pharmaceutical companies in the Gorlin Syndrome market includes:
HedgePath Pharmaceuticals
Mayne Pharma
PellePharm
Leo-Pharma
Phyton Biotech
And many others

For more detailed information on Gorlin Syndrome Market, visit:
https://www.delveinsight.com/report-store/gorlin-syndrome-market